Insights on the major trends in oncology including the development of targeted therapies in clinical trial designs and patient care.
The development of diagnostic tests which can predict patient response to these therapies are crucial to the clinical success of an immunotherapy candidate. This webinar recording helps to:
Successive revolutions of prevention strategies and precision medicine in the past two decades have contributed to lowering the mortality rate for the ten most prevalent cancers by more than 10% across most of Europe, Asia, and North America. In the coming years, emergent therapeutic strategies, including immuno-oncologics and liquid biopsy-based companion diagnostics, may yield some of the most transformative clinical benefits to date. Yet, oncology pipelines remain rife with challenges. This whitepaper provides specific ideas and innovative approaches that make a real difference to the successful conduct of industry-sponsored clinical trials.Download the whitepaper
The goal of oncology drug development is to bring effective treatments and improved individual care to patients suffering from cancer. The process to get a new therapy approved by the FDA may take 10–15 years and requires the timely completion of numerous clinical trials. The success of the process rests on finding and supporting the investigators and site staff that ultimately recruit the patients for the studies. CROs can reduce barriers to clinical research participation for sites, by finding ways to create administrative efficiencies, keep investigators engaged throughout the process,Download the whitepaper
Immuno-oncology (I-O) plays an increasingly important part in cancer treatment, utilising the body’s own immune system to fight the disease. Although not a new concept, I-O has progressed considerably in the last 10-15 years with approvals for numerous I-O therapies including vaccines, cytokines, tumour-directed monoclonal antibodies, and immune checkpoint inhibitors.Download the whitepaper
Dr. Brian Huber outlines the role biomarkers play in guiding therapeutic strategies.
Dr. Brian Huber discusses the shift from histology-based to lesion-based trial design in precision medicine (page 54-57).
An overview of the current treatment landscape, including cell and gene therapies, of and challenges that cancer research faces.
Evolvement of RWD collection in oncology in the coming years.
External pressures and rapid scientific advancements are changing oncology, and innovative trials are needed to keep pace.
Innovation in oncology drug development is driving more efficient and effective development of new cancer treatments.
Groundbreaking treatments involving adoptive cell transfer, such as CAR -T drugs, call for innovative commercialisation strategies.
ICON Oncology’s opinion of how we can reach for the stars with a moonshot. (PDF)
Five smarter approaches to trial design and analysis.
Recent innovation in clinical drug development and approval for oncology drugs.
Why transforming immuno-oncology trial design is a competitive necessity. (PDF)
The connection between sites and CROs has never been more important, as patient recruitment in oncology is heavily reliant on both in terms of trained investigators and service providers. (PDF)
Cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients.
Improved diagnostic technologies, prevention methods and the advent of targeted therapeutic approaches have together contributed to lowering the mortality rate for the 10 most prevalent cancers.
Advances in our understanding of cancer biology and the tumour microenvironment (TME), have led to the development of personalised drug and therapy designs to better prevent disease progression and relapse.
Scaling Up CAR-T Therapies Requires Overcoming Manufacturing, Regulatory and Distribution Challenges.
Patient centric strategies to focus more on patient needs and increase efficiencies.
Biostatistics: Using Restricted Mean Survival Time (RMST) in Oncology Trials to Improve Outcomes.
Biomarker-based methods and how they can be leveraged to add value to oncology trials.
ICON has been immersed in the development of both passive and active immunotherapy approaches, allowing sponsors to overcome challenges in Immuno-Oncology.
The discovery of novel biomarkers has made MMMultiple Myeloma diagnosis and monitoring much easier and more efficient.
The evolution of adoptive cellular transfer (ACT) for the treatment of lymphoma, leukaemia and myeloma patients has grown exponentially.
Although Asia Pacific (APAC) is sometimes referred to as a homogenous unit, it is a heterogeneous region, with divergent countries, languages, populations and cultures.
Significant progress has been made in our understanding of the molecular lesions responsible for tumor cells.
Immunotherapy has been the focus of medical research for many years, and scientists continue to experiment with and learn about this form of therapy in cancer treatment.
ICON’s Oncology Solution expedites every aspect of a cancer drug trial. It combines global experience in all Phases of oncology drug development (including early phase, immuno-oncology and cell and gene therapies) with expertise in tumor imaging, laboratory (including PK/PD and Biomarkers) IVRS, central data management, electronic data capture and regulatory oncology issues.Read more about ICON's services in oncology